Celyad Oncology (CYAD) H1 2025 earnings summary

Executive summary

• Reported first half 2025 financial results, with a treasury position of €0.8 million as of June 30, 2025.

• Cash and cash equivalents projected to fund operations into Q4 2025 based on current forecasts.

Financial highlights

• Revenue for H1 2025 was €0.2 million, unchanged from H1 2024.

• Net loss for H1 2025 was €3.7 million (€0.09 per share), compared to €3.0 million (€0.07 per share) in H1 2024.

• Net cash used in operations increased to €3.3 million in H1 2025 from €2.8 million in H1 2024.

• No capital increase occurred in H1 2025; 41.4 million shares outstanding.

Outlook and guidance

• Existing cash and cash equivalents expected to cover estimated operating and capital expenditures into Q4 2025.